Its expression was observed significantly increase in the advanced stage (stage III/ IV) relative to early-stage (stage I/ II) in ACC, BRCA, KIRC, and TGCT, suggesting a role for SLC25A1 in tumor suppression. Here, SLC25A1 is linked to adrenal cortex carcinoma.